在全球疫情最嚴重的2020年3月，柏林夏洛特大學綜合醫(yī)院肌肉骨骼外科中心行政院長、AO Trauma德國區(qū)主席St?ckle教授正式與我們合作。2021年，他先后兩次與北京積水潭醫(yī)院王滿宜教授團隊舉行了中德創(chuàng)傷外科全球直播。2022年，他接收了來自武漢、重慶、佛山、貴陽的四位臨床醫(yī)學MD博士以及一位來自武漢中西醫(yī)結(jié)合骨科醫(yī)院的訪問學者，并幫助其中兩位符合條件的申請人獲得了國家留學基金委CSC獎學金。他們均于2023年抵達柏林在St?ckle教授的指導下開始學習。2023年9月，在經(jīng)過近24小時的長途旅行后，St?ckle教授在疫情后第一次受仁醫(yī)醫(yī)療邀請訪問中國三甲醫(yī)院，在廣州市第一人民醫(yī)院進行了為期一周的客座教授訪問。同年，他被任命為德國創(chuàng)傷外科學會2025年主席。2024年初，他接收了一位來自山西醫(yī)科大學的臨床醫(yī)學MD博士以及一位來自南方醫(yī)科大學順德醫(yī)院的訪問學者，并在3月抽空為博士申請人準備了申請國家留學基金委CSC獎學金所需的材料。四年來，我們共通了近600封郵件，進行了30次內(nèi)部視頻會議。在博士生抵達德國前，他主動要求與我們每月進行一次內(nèi)部視頻會議，溝通各博士生的申請進度。博士生抵達德國后，他每周組織一次組會，要求各博士生匯報各自課題進展，并堅持每兩周與我們進行一次視頻會議討論各合作項目進展。在每次會議中，他都高度認可我們選送的博士生的學習態(tài)度及取得的進展，尤其是來自武漢中西醫(yī)結(jié)合骨科醫(yī)院的王超群醫(yī)生。王醫(yī)生于2023年9月抵達柏林，在國家留學基金委員會的資助下開始了他的博士學習。正式注冊為柏林夏洛特醫(yī)科大學學生后，他積極參與科室的臨床活動、德國國內(nèi)的學術(shù)會議，在教授的要求和指導下大量閱讀文獻、學習英語，同時開始博士課題的工作。St?ckle教授夸贊半年多來王醫(yī)生的英語取得了長足的進步，每次都能高質(zhì)高效完成教授布置的任務。本周五St?ckle教授將從法蘭克福直飛上海，并于4月15日起，聯(lián)合深圳市第二人民醫(yī)院大骨科主任、AO亞太區(qū)前任主席、中華醫(yī)學會骨科分會創(chuàng)傷骨科學組名譽組長王滿宜教授及深圳市第二人民醫(yī)院創(chuàng)傷骨科主任張勝利教授開展為期一周的客座教授活動，此次活動將是AO診療及教育理念在中國的再次深化。

The cooperation between Gloryren and Prof. St?ckle, the Managing Director of the Center for Musculoskeletal Surgery of Charité and President of AO Trauma Germany, officially started in March 2020, when the healthcare system worldwide was hit severely by the pandemic. In 2021, jointly with Prof. WANG Manyi’s team at Beijing Jishuitan Hospital, he attended two Sino-German Global Webcast on Trauma Surgery. In 2022, he accepted 4 MD students from Wuhan, Chonqing, Foshan and Guiyang and 1 fellow from Wuhan Orthopaedics Hospital of Integrated Traditional Chinese and Western Medicine, two of which successfully got funding from the China Scholarship Council with great support from Prof. St?ckle. In September 2023, after a nearly 24-hour long journey, Prof. St?ckle visited China for the first time after the pandemic. He visited Guangzhou First People’s Hospital for one week as an international visiting professor. In the same year, he was elected as the President of German Society for Trauma Surgery 2025. In 2024, he accepted an MD student from Shanxi Medical University and a fellow from Shunde Hospital of Southern Medical University. During the last four years, we have exchanged nearly 600 emails and had 30 internal video conferences. Before the MD students arrived in Germany, Prof. St?ckle had a video conference per month with us to discuss the application status of each student. After they arrived in Germany, Prof. St?ckle called for group meeting every week with the MD students and a video conference with Gloryren every two weeks to discuss the progress of each project. Prof. St?ckle highly acknowledged the ambition and motivation of the MD students and the progress they’ve made during each video conference. He specifically commented the performance of WANG Chaoqun from Wuhan Orthopaedics Hospital of Integrated Traditional Chinese and Western Medicine. Wang arrived in Berlin in September 2023 and started his doctoral studies funded by China Scholarship Council. After officially enrolled as an MD student at Charité – Berlin University Medicine, Wang has been actively involved in daily clinical activities, national meetings, reading relevant literature, improving language proficiency, and started his doctoral project. Prof. St?ckle complimented Wang on the great progress he has made in English over the past seven months, and his capability to complete all the assignments with high quality and efficiency. Prof. St?ckle will take a direct flight from Frankfurt to Shanghai on coming Friday. Together with Prof. WANG Manyi, Director of Orthopedics of Shenzhen Second People’s Hospital, past President of AO Asia Pacific, Honorary President of the Trauma Branch of Chinese Orthopedic Association, and Prof. ZHANG Shengli, Director of Orthopedic Trauma of Shenzhen Second People’s Hospital, Prof. St?ckle will carry out a one-week visiting professorship activity from April 15. The planned activity will further deepen the AO concept of treatment and education in China.